11 results on '"Palop, Begoña"'
Search Results
2. The treatment of bacterial biofilms cultivated on knee arthroplasty implants using the bioelectric effect.
- Author
-
Tamimi, Iskandar, Gasca, María, Halbardier, Alexandra, Martin, Sergio, Martin Caballero, Gregorio, Lucena Serrano, Cristina, Martin, Elena, Tamimi, Faleh, González-Quevedo, David, García de Quevedo, David, Sobrino, Beatriz, Palop, Begoña, Guerado, Enrique, Pérez Lara, Almudena, Urdiales, Cristina, and Gómez de Gabriel, Jesús Manuel
- Published
- 2024
- Full Text
- View/download PDF
3. Current status of hepatitis delta in Andalusia: multicenter study
- Author
-
Casado, Marta, primary, Castillo, Anny Camelo, additional, Baena, Pilar Barrera, additional, Perez Jimenez, Ana Belen, additional, Bandera, Jose Pinazo, additional, Viciana, Isabel, additional, Aguilar, Juan Cristobal, additional, Carlos, Juan, additional, Arboledas, Alados, additional, SantaMaria Rodriguez, German Jose, additional, Freyre, Carolina, additional, Villalba, Carmen Molina, additional, Coronas, Joaquin Salas, additional, Luzón-García, M. Pilar, additional, Ruiz, Elena, additional, Fernandez, Teresa Cabezas, additional, del Pino, Pilar, additional, De La Luna, Francisco Franco Álvarez, additional, Cordero, Patricia, additional, Arellano, Encarnación Ramirez, additional, Giráldez-Gallego, Alvaro, additional, Lozano Domínguez, María Carmen, additional, Lopez Garrido, Maria Angeles, additional, Sampedro, Antonio, additional, González-Grande, Rocio, additional, Palop, Begoña, additional, Macías, Manuel, additional, Montiel, Natalia, additional, Molina, Laura Castillo, additional, Roldan, Carolina, additional, Fernández, Carmen Sendra, additional, De La Iglesia Salgado, Alberto, additional, Mate, Carlota Jimeno, additional, del Carmen Domínguez, Maria, additional, Fernández-Sánchez, Fernando, additional, Rosales Zabal, Jose Miguel, additional, and Garcia, Federico Garcia, additional
- Published
- 2023
- Full Text
- View/download PDF
4. FRI-409 Enhancing hepatitis delta diagnosis in southern Spain: efficacy and cost-effectiveness of double reflex testing
- Author
-
Fuentes, Ana, de Salazar, Adolfo, Chaves-Blanco, Lucía, Ruiz-Escolano, Elena, Montiel, Natalia, Macías, Manuel, Odero, Valle, Aguilar, Juan Cristobal, Pérez, Ana Belén, Barrera, Pilar, Fernandez, Teresa Cabezas, Castillo, Anny Camelo, Palop, Begoña, González-Grande, Rocio, García-Barrionuevo, Aurora, Pinazo-Bandera, Jose María, Sánchez, Fernando Fernández, Domínguez, María Carmen Lozano, Giraldez, Alvaro, del Carmen Domínguez, Maria, Jimeno-Mate, Carlota, Arellano, Encarnación Ramirez, Cordero, Patricia, De La Luna, Francisco Franco Álvarez, del Pino, Pilar, De La Iglesia Salgado, Alberto, Sendra-Fernández, Carmen, Sampedro, Antonio, López-Garrido, M. Ángeles, Luzón-García, M. Pilar, Molina-Villalba, Carmen, Salas, Joaquin, Roldan, Carolina, Castillo-Molina, Laura, García, Fernando García, Freyre, Carolina, Santamaría-Rodríguez, Germán, Rosales, José María, Domínguez-Hernández, Raquel, Casado-Martin, Marta, and Garcia, Federico Garcia
- Published
- 2024
- Full Text
- View/download PDF
5. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections
- Author
-
Sojo Dorado, Jesús, López Hernández, Inmaculada, Rosso Fernández, Clara, Morales, Isabel M., Palacios Baena, Zaira R., Hernández Torres, Alicia, Merino de Lucas, Esperanza, Escolà Vergé, Laura, Bereciartua, Elena, García Vázquez, Elisa, Pintado, Vicente, Boix Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Nuria, Giner Oncina, Livia, Amador Prous, Concha, Shaw, Evelyn, Jover Saenz, Alfredo, Molina, Jose, Martínez Álvarez, Rosa M., Dueñas, Carlos J., Calvo Montes, Jorge, Silva, Jose T., Cárdenes, Miguel A., Lecuona, María, Pomar, Virginia, Valiente de Santis, Lucía, Yagüe Guirao, Genoveva, Lobo Acosta, María Angeles, Merino Bohórquez, Vicente, Pascual, Alvaro, Rodríguez Baño, Jesús, Almirante, Benito, Fernández, Mario, Paño Pardo, José Ramón, Cueto, Marina de, Retamar Gentil, Pilar, López Cortés, Luis Eduardo, Gutiérrez Gutiérrez, Belén, Docobo, Fernando, Borreguero, Irene, Camean, Manuel, Moral Escudero, Encarnación, Pareja Rodríguez de Vera, Ana, Martínez Toldos, María del Carmen, Blázquez Abellán, Ana, Belles Belles, Alba, Ramírez Hidalgo, María Fernanda, Mirelis, Beatriz, Calbo, Esther, Xercavins, Mariona, Gracia Ahufinger, Irene, Cano Yuste, Angela M., Guío, Laura, Hernandez, Jose Luis, Pigrau Serrallach, Carlos, Viñado Pérez, Belen, Puig Asensio, Mireia, Ardanuy, Carmen, Pujol, Miquel, García Rosado, Dácil, Gil Anguita, Concepción, Siverio, Ana, Gimeno Gascón, Adelina, Boix Martínez, Vicente, Reus Bañuls, Sergio, Agea Durán, Iván, Fariñas, Carmen, Palop, Begoña, Vilchez, Helem, Lepe, José Antonio, Gil Navarro, María Victoria, San Juan, Rafael, Chaves, Fernando, Escudero, Rosa, Gioia, Francesca, Sánchez Díaz, Ana María, Cañas Pedrosa, Ana, Sangil Monroy, Nayra, Toyas Miazza, Carla, and Reipi Geiras Forest Group
- Subjects
Escheríchia coli ,Infeccions del tracte urinari ,Escherichia coli ,Urinary tract infections - Abstract
IMPORTANCE The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. OBJECTIVE To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. INTERVENTIONS Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or pa renteral ertapenem for the comparator group after 4 days. MAIN OUTCOMES AND MEASURES The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. RESULTS Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to infinity percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI. -infinity to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01). CONCLUSIONS AND RELEVANCE This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections.
- Published
- 2022
6. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa
- Author
-
Herrera, F., Cuervo, Guillermo, Carratalà, J., Novo, A., Manzur, A., Tilley, R., Yáñez, L., Del Pozo, J.L., Peghin, M., Araos, R., Hemmatti, P., Gomes, M.Z.R., Marin, J.I., Márquez-Gómez, I., Calik, S., Sipahi, O.R., Kanj, S.S., Montero, M., Maestro-De La Calle, G., Morales, I., Kern, W.V., Isler, B., García, E., Brunel, A.-S., Paz Morales, H., Drgona, L., Gasch, O., Tubau, Fe, Escrihuela-Vidal, Francesc, Martín-Dávila, P., Aguado, José María, Horcajada, Juan Pablo, Mikulska, M., Tebé, Cristian, Arias, Marisol Rodríguez, Aguilar-Company, Juan, Larrosa, Nieves, Cardozo, Celia, Garcia-Vidal, Carolina, Karim-Yaqub, Ibrahim, Greco, Raffaella, Montejo, M., AKOVA, MURAT, Oltolini, C., Abdala, E., Puerta-Alcalde, P., Ruiz-Camps, I., Mussetti, A., Pallarès, N., Laporte-Amargós, J., Albasanz-Puig, A., Gudiol, C., Cichero, Paola, Ayaz, Caglayan Merve, Céspedes, Roberto, López-Soria, Leire, Magnasco, Laura, Fortún, Jesús, Torres, Diego, Boté, Anna, Espasa, Mateu, Montaguti, Mia Hold, Bochud, Pierre-Yves, Manuel, Oriol, Carrasco, Salvador Tabares, López, Josefina Serrano, Bertz, Hartmut, Rieg, Siegbert, De Cueto, Marina, Rodríguez-Baño, Jesús, Lizasoain, Manuel, Sangro Del Alcázar, Paloma, Castaldo, Nadia, Bassetti, Matteo, Munita, Jose, Maschmeyer, Georg, Tonhá, João Pedro Silva, Aparecida Da Silva Machado, Amanda, Correa, Lina Clemencia, Palop, Begoña, Nazli-Zeka, Arzu, Uyan-Onal, Ayse, Jabbour, Jean-Francois, El Zein, Saeed, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), Red Española de Investigación en Patología Infecciosa, European Commission, Promex Stiftung Fur Die Forschung, Gilead Sciences, MSD, Astellas Pharma, Novartis, Pfizer, and Ege Üniversitesi
- Subjects
Male ,Carbapenem ,Bacteremia ,predictive model ,0302 clinical medicine ,Risk Factors ,Drug Resistance, Multiple, Bacterial ,Neoplasms ,Pharmacology (medical) ,030212 general & internal medicine ,Antibiotic prophylaxis ,Cancer ,0303 health sciences ,Middle Aged ,Antibiotic coverage ,Anti-Bacterial Agents ,Infectious Diseases ,Treatment Outcome ,Pseudomonas aeruginosa ,Female ,medicine.drug ,medicine.medical_specialty ,Neutropenia ,Antibiotic sensitivity ,bloodstream infection ,Microbial Sensitivity Tests ,Tazobactam ,Models, Biological ,Epidemiology and Surveillance ,03 medical and health sciences ,Internal medicine ,medicine ,cancer ,Humans ,Pseudomonas Infections ,multidrug resistant, Pseudomonas aeruginosa, bacteremia, bloodstream infection, neutropenia, cancer, risk factors, predictive model ,Retrospective Studies ,Pharmacology ,030306 microbiology ,business.industry ,multidrug resistant ,Retrospective cohort study ,Odds ratio ,Multidrug resistant ,Risk factors ,ROC Curve ,Predictive model ,Bloodstream infections ,business ,Bloodstream infection ,Piperacillin - Abstract
We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) Pseudomonas aeruginosa in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to P. aeruginosa conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. of a total of 1,217 episodes of BSI due to P. aeruginosa, 309 episodes (25.4%) were caused by MDR strains. the rate of multidrug resistance increased significantly over the study period (P = 0.033). Predictors of MDR P. aeruginosa BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR), 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR P. aeruginosa. the application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development., ESGBIES study group; ESGICH study group; Spanish Plan Nacional de I+D+i 2013-2016; Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/0001]; European Development Regional Fund A Way To Achieve Europe, Operative Program Intelligent Growth 2014-2020; Promex Stiftung fur die Forschung (Carigest SA); GileadGilead Sciences; PfizerPfizer, We thank the ESGBIES and the ESGICH study groups for supporting the study.; This study was supported by the Spanish Plan Nacional de I+D+i 2013-2016 and the Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (grant REIPI RD16/0016/0001), cofinanced by the European Development Regional Fund A Way To Achieve Europe, Operative Program Intelligent Growth 2014-2020.; A.-S.B. received a grant from Promex Stiftung fur die Forschung (via Carigest SA) and funding from Gilead to attend the ECCMID Congress (2018). O.R.S. received speaker honoraria from MSD, Astellas, Novartis, and Pfizer. S.S.K. received speaker honoraria from Pfizer, MSD, Astellas. F.H. received speaker honoraria from MSD, and Pfizer and a research and educational grant from Pfizer. the rest of the authors declare no conflicts of interest.
- Published
- 2020
7. WED-208 - Current status of hepatitis delta in Andalusia: multicenter study
- Author
-
Casado, Marta, Castillo, Anny Camelo, Baena, Pilar Barrera, Perez Jimenez, Ana Belen, Bandera, Jose Pinazo, Viciana, Isabel, Aguilar, Juan Cristobal, Carlos, Juan, Arboledas, Alados, SantaMaria Rodriguez, German Jose, Freyre, Carolina, Villalba, Carmen Molina, Coronas, Joaquin Salas, Luzón-García, M. Pilar, Ruiz, Elena, Fernandez, Teresa Cabezas, del Pino, Pilar, De La Luna, Francisco Franco Álvarez, Cordero, Patricia, Arellano, Encarnación Ramirez, Giráldez-Gallego, Alvaro, Lozano Domínguez, María Carmen, Lopez Garrido, Maria Angeles, Sampedro, Antonio, González-Grande, Rocio, Palop, Begoña, Macías, Manuel, Montiel, Natalia, Molina, Laura Castillo, Roldan, Carolina, Fernández, Carmen Sendra, De La Iglesia Salgado, Alberto, Mate, Carlota Jimeno, del Carmen Domínguez, Maria, Fernández-Sánchez, Fernando, Rosales Zabal, Jose Miguel, and Garcia, Federico Garcia
- Published
- 2023
- Full Text
- View/download PDF
8. Clinical and immunoserological status 12 weeks after infection with COVID-19: prospective observational study
- Author
-
Santis, Lucía Valiente-De, primary, Pérez-Camacho, Inés, additional, Sobrino, Beatriz, additional, González, Gracia Eugenia, additional, Ruíz-Mesa, Juan Diego, additional, Plata, Antonio, additional, Márquez-Gómez, Ignacio, additional, Delgado-Fernández, Marcial, additional, Castaño, Manuel, additional, Oñate, Francisco, additional, Orihuela, Francisco, additional, Palop, Begoña, additional, and María Reguera, José, additional
- Published
- 2020
- Full Text
- View/download PDF
9. Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: A 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study
- Author
-
Fenoll, Asunción, Ardanuy Tisaire, María Carmen, Liñares Louzao, Josefina, Cercenado, Emilia, Marco Reverté, Francesc, Fleites, Ana, Rodríguez Mayo, María, López Hontangas, Jose Luis, Palop, Begoña, Aller, Ana Isabel, Buendía, Buenaventura, Méndez, Cristina, Cifuentes, Isabel, and ODIN Study Group
- Subjects
Male ,0301 basic medicine ,Streptococcus pneumonia ,Clonal complex ,PCV13 ,Bacteremia ,Pneumònia ,medicine.disease_cause ,Pneumococcal Vaccines ,0302 clinical medicine ,Levofloxacin ,Epidemiology ,Prospective Studies ,030212 general & internal medicine ,Pneumococs ,Invasive pneumococcal disease ,Middle Aged ,Hospitalization ,Vaccination ,Streptococcus pneumoniae ,Infectious Diseases ,Epidemiological Monitoring ,Molecular Medicine ,Female ,Meningitis ,medicine.drug ,Adult ,medicine.medical_specialty ,Genotype ,030106 microbiology ,Erythromycin ,Serogroup ,Pneumococcal Infections ,Serotype ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Serotyping ,Aged ,General Veterinary ,General Immunology and Microbiology ,business.industry ,Public Health, Environmental and Occupational Health ,Pneumonia ,medicine.disease ,bacterial infections and mycoses ,Spain ,business ,Licensure - Abstract
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccination strategies. The aim of this study was to assess the epidemiology of IPD in adults (>= 18 years) after PCV13 introduction for children: serotypes, clonal complexes, antibiotic non-susceptibility and clinical presentations. We performed a prospective, clinical surveillance of hospitalized culture-confirmed IPDs in adults in nine Spanish hospitals (August 2010-June 2015). A total of 1087 culture-confirmed IPD episodes were included, of which 772 (71.0%) had bacteremic pneumonia (401 complicated/371 uncomplicated pneumonia), 122 (11.2%) meningitis, 102 (9.4%) non-focal bacteremia, 34 (3.1%) peritonitis and 57 (5.3%) others. The most common serotypes were: 3 (12.7%), 19A (8.5%), 8 (7.7%), 7F (6.3%), 1 (4.2%), 6C (4.2%), 11A (4.2%), 22F (4.2%) and 14 (4.0%). Vaccine types (PCV13 + 6C) caused 49.8% of IPD episodes, with a significant decrease over the 5-year period, and significant decreases in serotypes 6C and 7F. The most common genotypes were: CC180 (8.4%), CC191 (6.0%), and CC53 (5.0%). Vaccine types caused 53.9% (414/768) pneumonia episodes and 58.9% (235/399) complicated pneumonia, 53.4% IPD in adults
- Published
- 2018
10. Clinical and epidemiological features and prognosis of complicated pyelonephritis: a prospective observational single hospital-based study
- Author
-
Buonaiuto, Veronica A, primary, Marquez, Ignacio, additional, De Toro, Inmaculada, additional, Joya, Carolina, additional, Ruiz-Mesa, Juan D, additional, Seara, Raimundo, additional, Plata, Antonio, additional, Sobrino, Beatriz, additional, Palop, Begoña, additional, and Colmenero, Juan D, additional
- Published
- 2014
- Full Text
- View/download PDF
11. Serotypes and genotypes of S. pneumoniae isolates from adult invasive disease in Spain: A 5-year prospective surveillance after pediatric PCV13 licensure. The ODIN study.
- Author
-
Fenoll A, Ardanuy C, Liñares J, Cercenado E, Marco F, Fleites A, Rodríguez-Mayo M, López-Hontangas JL, Palop B, Aller AI, Buendía B, Méndez C, and Cifuentes I
- Subjects
- Adult, Aged, Female, Genotype, Hospitalization, Humans, Licensure, Male, Middle Aged, Pneumococcal Infections microbiology, Pneumococcal Vaccines therapeutic use, Prospective Studies, Serogroup, Serotyping, Spain epidemiology, Streptococcus pneumoniae isolation & purification, Young Adult, Bacteremia epidemiology, Epidemiological Monitoring, Pneumococcal Infections epidemiology, Pneumococcal Vaccines administration & dosage, Streptococcus pneumoniae genetics
- Abstract
Serotypes/genotypes causing invasive pneumococcal disease (IPD) in adults are determined by vaccination strategies. The aim of this study was to assess the epidemiology of IPD in adults (≥18 years) after PCV13 introduction for children: serotypes, clonal complexes, antibiotic non-susceptibility and clinical presentations. We performed a prospective, clinical surveillance of hospitalized culture-confirmed IPDs in adults in nine Spanish hospitals (August 2010-June 2015). A total of 1087 culture-confirmed IPD episodes were included, of which 772 (71.0%) had bacteremic pneumonia (401 complicated/371 uncomplicated pneumonia), 122 (11.2%) meningitis, 102 (9.4%) non-focal bacteremia, 34 (3.1%) peritonitis and 57 (5.3%) others. The most common serotypes were: 3 (12.7%), 19A (8.5%), 8 (7.7%), 7F (6.3%), 1 (4.2%), 6C (4.2%), 11A (4.2%), 22F (4.2%) and 14 (4.0%). Vaccine types (PCV13 + 6C) caused 49.8% of IPD episodes, with a significant decrease over the 5-year period, and significant decreases in serotypes 6C and 7F. The most common genotypes were: CC180 (8.4%), CC191 (6.0%), and CC53 (5.0%). Vaccine types caused 53.9% (414/768) pneumonia episodes and 58.9% (235/399) complicated pneumonia, 53.4% IPD in adults <50 years (143/268), and 54.7% IPD in immunocompetent patients (337/616). Overall non-susceptibility was 25.9% to penicillin (1.1% for parenteral criteria), 24.9% to erythromycin and 2.7% to levofloxacin. CONCLUSIONS: Although the percentage of vaccine-types causing IPDs in adults significantly decreased, it remained high. Associations of vaccine types with pneumonia (with complicated pneumonia for specific serotypes), and immunocompetent patients point to the burden of IPD caused by PCV13 serotypes., (Copyright © 2018 Elsevier Ltd. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.